N-(Phosphonacetyl)-l-aspartate (PALA) in advanced breast cancer: a phase II trial of the EORTC breast cancer cooperative group |
| |
| Affiliation: | 2. Service de Médecine et Laboratoire d''Investigation Clinique H. J. Tagnon, Institut Jules Bordet, 1, rue Héger-Bordet, 1000 Bruxelles, Belgium;1. Department of Quality Assessment, Health Insurance Review & Assessment Service, Republic of Korea;2. Department of Public Health, Graduate School, Yonsei University, Republic of Korea;3. Institute of Health Services Research, College of Medicine, Yonsei University, Republic of Korea;4. Institute for Health and Social Affairs, Health Security Research Division, Republic of Korea;5. Department of Preventive Medicine, College of Medicine, Yonsei University, Republic of Korea;1. Department of Preventive Medicine, Gachon University College of Medicine, Incheon, Republic of Korea;2. Gachon Advanced Institute for Health Sciences and Technology, Incheon, Republic of Korea;3. Gachon University Gil Medical Center, Incheon, Republic of Korea;1. Aix-Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, Department of Medical Oncology, CRCM, Marseille, France;2. Institut Curie – Hôpital René Huguenin, Saint-Cloud, France;3. Centre Georges-Francois Leclerc, Dijon, France;4. Institut de Cancérologie de L''Ouest, Nantes, France;5. Institut Paoli-Calmettes, Department of Clinical Research and Innovations, Marseille, France;6. Aix-Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, Department of Biopathology, CRCM, Marseille, France;7. Aix Marseille University, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de La Santé & Traitement de L''Information Médicale, Marseille, France;1. Pharmacotherapeutics Unit, Department of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Selangor, Malaysia;2. Clinical Oncology Unit, University Malaya Medical Centre, Kuala Lumpur, Malaysia;3. Department of Radiotherapy and Oncology, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Kuala Lumpur, Malaysia |
| |
| Abstract: | ![]()
Twenty-nine evaluable patients with extensively pretreated breast cancer received PALA, a new pyrimidine antimetabolite. The drug was given by intravenous infusion over 60 min, at a daily dose of 2.5 g/m2 for 2 consecutive days. Courses were repeated at 2-week intervals and doses were escalated to toxicity. Two objective partial remissions were observed, lasting for 3 and 4.5 months respectively. Toxic effects were dose-related and consisted mainly of mucocutaneous manifestations, i.e., skin rashes, stomatitis, diarrhea, conjunctivitis and corneal ulcerations. Evidence of antitumor potential in far-advanced disease and lack of myelosuppression point to the need for additional trials of PALA in a more favorable selection of patients with breast cancer. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
